Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 1981 AL 1995

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, Gueorguieva I, Hauck PM, Brooks DA, Mintun MA, Sims JR.

JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793.

BChE inhibitors from marine organisms - A review

Lins Alves LK, Cechinel Filho V, de Souza RLR, Furtado-Alle L.

Chem Biol Interact. 2022 Nov 1;367:110136. doi: 10.1016/j.cbi.2022.110136. Epub 2022 Sep 9.

Review of lipoic acid: From a clinical therapeutic agent to various emerging biomaterials

Lv SY, He S, Ling XL, Wang YQ, Huang C, Long JR, Wang JQ, Qin Y, Wei H, Yu CY.

Int J Pharm. 2022 Nov 5;627:122201. doi: 10.1016/j.ijpharm.2022.122201. Epub 2022 Sep 14.

Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil

Tariot PN, Braeckman R, Oh C.

J Alzheimers Dis. 2022;90(1):161-172. doi: 10.3233/JAD-220530.

An insight into the neuroprotective effects and molecular targets of pomegranate (Punica granatum) against Alzheimer's disease

George N, AbuKhader M, Al Balushi K, Al Sabahi B, Khan SA.

Nutr Neurosci. 2023 Oct;26(10):975-996. doi: 10.1080/1028415X.2022.2121092. Epub 2022 Sep 20.

Effects of Hypertension on Alzheimer's Disease and Related Disorders

Malone JE, Elkasaby MI, Lerner AJ.

Curr Hypertens Rep. 2022 Dec;24(12):615-625. doi: 10.1007/s11906-022-01221-5. Epub 2022 Sep 20.

Recent Advances in the Neuroprotective Properties of Ferulic Acid in Alzheimer's Disease: A Narrative Review

Di Giacomo S, Percaccio E, Gullì M, Romano A, Vitalone A, Mazzanti G, Gaetani S, Di Sotto A.

Nutrients. 2022 Sep 8;14(18):3709. doi: 10.3390/nu14183709.

Development of new Alzheimer's disease drug candidates using donepezil as a key model

Eissa KI, Kamel MM, Mohamed LW, Kassab AE.

Arch Pharm (Weinheim). 2023 Jan;356(1):e2200398. doi: 10.1002/ardp.202200398. Epub 2022 Sep 23.

Cdk5-p25 as a key element linking amyloid and tau pathologies in Alzheimer's disease: Mechanisms and possible therapeutic interventions

Maitra S, Vincent B.

Life Sci. 2022 Nov 1;308:120986. doi: 10.1016/j.lfs.2022.120986. Epub 2022 Sep 21.

Therapeutic approaches of nutraceuticals in the prevention of Alzheimer's disease

Pandey SN, Singh G, Semwal BC, Gupta G, Alharbi KS, Almalki WH, Albratty M, Najmi A, Meraya AM.

J Food Biochem. 2022 Dec;46(12):e14426. doi: 10.1111/jfbc.14426. Epub 2022 Sep 28.

Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target

Mandlik DS, Mandlik SK, S A.

Int J Neurosci. 2024 Jun;134(6):603-619. doi: 10.1080/00207454.2022.2130297. Epub 2022 Oct 10.

Clinical efficacy of acupuncture combined with Western medicine in the treatment of mild to moderate Alzheimer disease: A protocol of a randomized controlled trial

Zhou K, He J, Quan L, Guo R.

Medicine (Baltimore). 2022 Sep 30;101(39):e30705. doi: 10.1097/MD.0000000000030705.

Estrogen and dementia

Rocca WA, Faubion SS.

Maturitas. 2022 Nov;165:120-121. doi: 10.1016/j.maturitas.2022.05.005. Epub 2022 May 25.

A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance

Blivet G, Relano-Gines A, Wachtel M, Touchon J.

J Alzheimers Dis. 2022;90(2):811-822. doi: 10.3233/JAD-220467.

The effects of fenugreek seed extract supplementation in patients with Alzheimer's disease: A randomized, double-blind, placebo-controlled trial

Foroumandi E, Javan R, Moayed L, Fahimi H, Kheirabadi F, Neamatshahi M, Shogofteh F, Zarghi A.

Phytother Res. 2023 Jan;37(1):285-294. doi: 10.1002/ptr.7612. Epub 2022 Oct 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias